株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

がん免疫療法の世界市場予測:モノクロナール抗体・チェックポイント阻害薬・免疫調節薬・ワクチン・細胞療法

Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), And End User- Global Forecast To 2024

発行 Meticulous Market Research Pvt. Ltd. 商品コード 737756
出版日 ページ情報 英文 173 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
がん免疫療法の世界市場予測:モノクロナール抗体・チェックポイント阻害薬・免疫調節薬・ワクチン・細胞療法 Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), And End User- Global Forecast To 2024
出版日: 2018年11月01日 ページ情報: 英文 173 Pages
概要

当レポートでは、世界のがん免疫療法市場について調査分析し、市場概要、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場考察

  • イントロダクション
  • 促進要因
  • 抑制要因
  • 市場機会
  • 市場課題

第5章 産業考察

  • 主な産業動向
  • がん免疫療法の進化
  • オプジーボとキイトルーダ:がん免疫療法市場における主要製品

第6章 がん免疫療法市場:タイプ別

  • イントロダクション
  • モノクロナール抗体
  • チェックポイント阻害薬
  • 免疫調節薬
  • ワクチン
  • 細胞療法

第7章 がん免疫療法市場:用途別

  • イントロダクション
  • 肺癌
  • 乳癌
  • 大腸癌
  • メラノーマ
  • 前立腺癌
  • 多発性骨髄腫
  • その他の癌

第8章 がん免疫療法市場:エンドユーザー別

  • 概要
  • 病院
  • 診療所・その他

第9章 がん免疫療法市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合情勢

  • イントロダクション
  • 市場シェア分析
  • 競合企業のベンチマーキング
  • 競合状況・動向

第11章 企業プロファイル

  • Astrazeneca
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche
  • Celgene Corporation

第12章 付録

図表

List of Tables

  • Table 1: Major Cancer Immunotherapy Drugs Approved (2015-2017)
  • Table 2: Recent Developments in Cancer Immunotherapy Market in China
  • Table 3: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 4: Cancer Immunotherapy Market, by Country/Region, 2016-2024 ($Million)
  • Table 5: Key Monoclonal Antibodies Approved for Cancer Immunotherapy
  • Table 6: Key Conjugated Antibodies for Cancer Immunotherapy
  • Table 7: Monoclonal Antibodies Market, by Country/Region, 2016-2024 ($Million)
  • Table 8: Major FDA Approved PD-1 and PD-L1 Inhibitors
  • Table 9: Checkpoint Inhibitors Market, by Country/Region, 2016-2024 ($Million)
  • Table 10: Key Immunomodulators Available in the Market
  • Table 11: Immunomodulators Market, by Country/Region, 2016-2024 ($Million)
  • Table 12: Cancer Vaccines Market, by Country/Region, 2016-2024 ($Million)
  • Table 13: Cell Therapies Market, by Country/Region, 2016-2024 ($Million)
  • Table 14: Cancer Immunotherapy Market, by Application, 2016-2024 ($Million)
  • Table 15: Lung Cancer Immunotherapy Market, by Country/Region, 2016-2024 ($Million)
  • Table 16: Breast Cancer Immunotherapy Market, by Country/Region, 2016-2024 ($Million)
  • Table 17: Colorectal Cancer Immunotherapy Market, by Country/Region, 2016-2024 ($Million)
  • Table 18: Melanoma Immunotherapy Market, by Country/Region, 2016-2024 ($Million)
  • Table 19: Prostate Cancer Immunotherapy Market, by Country/Region, 2016-2024 ($Million)
  • Table 20: Multiple Myeloma: Recent Developments from Leading Players
  • Table 21: Multiple Myeloma Immunotherapy Market, by Country/Region, 2016-2024 ($Million)
  • Table 22: Other Cancer Immunotherapy Market, by Country/Region, 2016-2024 ($Million)
  • Table 23: Cancer Immunotherapy Market, by End User, 2016-2024 ($Million)
  • Table 24: Hospital Market for Cancer Immunotherapy, by Country/Region, 2016-2024 ($Million)
  • Table 25: Clinics and Others Market for Cancer Immunotherapy, by Country/Region, 2016-2024 ($Million)
  • Table 26: North America Cancer Immunotherapy Market, by Country, 2016-2024 ($Million)
  • Table 27: North America: Market, by Type, 2016-2024 ($Million)
  • Table 28: North America: Market, by Application, 2016-2024 ($Million)
  • Table 29: North America: Market, by End User, 2016-2024 ($Million)
  • Table 30: Leading Sites of New Cancer Cases (2017)
  • Table 31: Us: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 32: Us: Market, by Application, 2016-2024 ($Million)
  • Table 33: Us: Market, by End User, 2016-2024 ($Million)
  • Table 35: Canada: Cancer Immunotherapy Market, by Application, 2016-2024 ($Million)
  • Table 36: Canada: Market, by End User, 2016-2024 ($Million)
  • Table 37: Europe Cancer Immunotherapy Market, by Country, 2016-2024 ($Million)
  • Table 38: Europe: Market, by Type, 2016-2024 ($Million)
  • Table 39: Europe: Market, by Application, 2016-2024 ($Million)
  • Table 40: Europe: Market, by End User, 2016-2024 ($Million)
  • Table 41: Germany: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 42: Germany: Market, by Application, 2016-2024 ($Million)
  • Table 43: Germany: Market, by End User, 2016-2024 ($Million)
  • Table 44: France: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 45: France: Market, by Application, 2016-2024 ($Million)
  • Table 46: France: Market, by End User, 2016-2024 ($Million)
  • Table 47: U.K.: Funding By National Cancer Research Institute, 2012
  • Table 48: U.K.: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 49: U.K.: Market, by Application, 2016-2024 ($Million)
  • Table 50: U.K.: Market, by End User, 2016-2024 ($Million)
  • Table 51: Italy: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 52: Italy: Market, by Application, 2016-2024 ($Million)
  • Table 53: Italy: Market, by End User, 2016-2024 ($Million)
  • Table 54: Spain: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 55: Spain: Market, by Application, 2016-2024 ($Million)
  • Table 56: Spain: Market, by End User, 2016-2024 ($Million)
  • Table 57: Rest of Europe: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 58: Rest of Europe: Market, by Application, 2016-2024 ($Million)
  • Table 59: Rest of Europe: Market, by End User, 2016-2024 ($Million)
  • Table 60: Asia Pacific Cancer Immunotherapy Market, by Country, 2016-2024 ($Million)
  • Table 61: Asia Pacific: Market, by Type, 2016-2024 ($Million)
  • Table 62: Asia Pacific: Market, by Application, 2016-2024 ($Million)
  • Table 63: Asia Pacific: Market, by End User, 2016-2024 ($Million)
  • Table 64: China: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 65: China: Market, by Application, 2016-2024 ($Million)
  • Table 66: China: Market, by End User, 2016-2024 ($Million)
  • Table 67: Japan: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 68: Japan: Market, by Application, 2016-2024 ($Million)
  • Table 69: Japan: Market, by End User, 2016-2024 ($Million)
  • Table 70: India: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 71: India: Market, by Application, 2016-2024 ($Million)
  • Table 72: India: Market, by End User, 2016-2024 ($Million)
  • Table 73: Rest of APAC: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 74: Rest of APAC: Market, by Application, 2016-2024 ($Million)
  • Table 75: Rest of APAC: Market, by End User, 2016-2024 ($Million)
  • Table 76: Latin America: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 77: Latin America: Market, by Application, 2016-2024 ($Million)
  • Table 78: Latin America: Market, by End User, 2016-2024 ($Million)
  • Table 79: Middle East and Africa: Cancer Immunotherapy Market, by Type, 2016-2024 ($Million)
  • Table 80: Middle East and Africa: Market, by Application, 2016-2024 ($Million)
  • Table 81: Middle East and Africa: Market, by End User, 2016-2024 ($Million)
  • Table 82: Key Products: Monoclonal Antibodies
  • Table 83: Key Products: Checkpoint Inhibitors
  • Table 84: Key Products: Immunomodulators
  • Table 85: Key Products: Vaccines
  • Table 86: Key Products: Cell Therapies

List of Figures

  • Figure 1: Global Cancer Immunotherapy Market, 2016-2024 ($ Million)
  • Figure 2: Cancer Immunotherapy: Global Market Outlook, by Type 2018 Vs. 2024
  • Figure 3: Cancer Immunotherapy: Global Market Outlook, by Application 2018 Vs. 2024
  • Figure 4: Cancer Immunotherapy: Global Market Outlook, by End User 2018 Vs. 2024
  • Figure 5: Cancer Immunootherapy: Regional Market Outlook, 2018 Vs. 2024
  • Figure 6: Market Overview: Cancer Immunotherapy Market
  • Figure 7: Global Cancer Incidence and Mortality (2018)
  • Figure 8: Cancer Therapy Deals Distribution (2012-2016)
  • Figure 9: Clinical Trials Check Point Inhibitors (2017)
  • Figure 10: R&D Expenditure of Major Players in Cancer Immunotherapy Market (2015 Vs 2017)
  • Figure 11: Cancer Incidence by Region (2018)
  • Figure 12: Per Capita Healthcare Expenditure In Selected Emerging Countries ($)
  • Figure 13: Improvement in 5 Year Survival Rates: Personalized Immunotherapy
  • Figure 14: Biopharmaceutical Companies Are Committed To Advancing Personalized Medicines
  • Figure 15: Clinical Trials for Cancer Immunotherapy in Combination
  • Figure 16: Opdivo (BMS) Vs Keytruda (Merck)
  • Figure 17: Distribution of Approved Monoclonal Antibody Drugs, by Indication
  • Figure 18: Number of Combination Studies for PD-1/PD-L1 Mab
  • Figure 19: Lung Cancer Statistics (2018)
  • Figure 20: PD-1 & PD-L1: New Clinical Trials and Average Enrolment Per New Trial
  • Figure 21: Breast Cancer Statistics (2018)
  • Figure 22: Colorectal Cancer Statistics (2018)
  • Figure 23: Melanoma Incidence Rate, 2016 (Per 100,000)
  • Figure 24: Prostate Cancer Statistics (2018)
  • Figure 25: Us Healthcare Spending ($ Billion)
  • Figure 26: Us Healthcare Spending ($ Billion)
  • Figure 27: Us: Country Health Profile (Cancer)
  • Figure 28: Canada: Cancer Incidence, by Type (2015)
  • Figure 29: Canada: Geriatric Population (Million)
  • Figure 30: Canada: Country Profile (Cancer)
  • Figure 31: Europe: Highest Share of Geriatric Population, 2010-2017
  • Figure 32: Germany: Country Health Profile (Cancer)
  • Figure 33: France: Country Health Profile
  • Figure 34: U.K.: Country Health Profile
  • Figure 35: Italy: Country Health Profile
  • Figure 36: Spain: Share of Clinical Trials in Oncology
  • Figure 37: Spain: Country Health Profile
  • Figure 38: Rest of Europe: Key Indicators
  • Figure 39: China: Clinical Trials (2012-2016)
  • Figure 40: China: Country Health Profile
  • Figure 41: Japan: Country Health Profile
  • Figure 42: India: Country Health Profile
  • Figure 43: Australia: Country Health Profile
  • Figure 44: Brazil: Country Health Profile
  • Figure 45: Key Strategy Adopted By Major Players in Market: Approvals
  • Figure 46: Market Share Analysis of Key Players
  • Figure 47: Cancer Immunotherapy: Competitive Benchmarking
目次

The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to reach USD 152.83 billion by 2024.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, opportunities, and challenges. The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market. However, high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.

Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five year survival rates as compared to other cancer treatment options available in market.

Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.

An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and Asia Pacific. The large share of this region is mainly attributed to the factors such as rising incidence of cancer globally, growing adoption of immunotherapy for cancer treatment, rising investments in collaboration and mergers, and enhancement in the drug development process owing to development of bioinformatics. Furthermore, the regulatory bodies such as US FDA and European Commission are specially focusing on the research of cancer immunotherapy due to the advantages of this therapy compared with other treatment options. The faster drug approval in the cancer immunotherapy is also responsible for growth of this market.

The key players profiled in the global cancer immunotherapy market research report are F. Hoffmann-La Roche, Celgene Corporation, Bristol-Myers Squibb, Merck & Co., Inc., Amgen Inc., ELI Lilly and Company, Janssen Global Services, LLC (Johnson and Johnson), Novartis, Pfizer, Inc., Gilead Sciences, Inc., Dendreon Pharmaceuticals, and Bayer among others.

Scope of the Report:

Market by Product

  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Immunomodulators
  • Vaccines
  • Cell Therapy

Market by Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Multiple Myeloma
  • Other Cancer Types

Market by End User

  • Hospitals
  • Clinics & Others

Market by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation
  • 1.3. Currency and Limitations
    • 1.3.1. Currency
    • 1.3.2. Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Secondary Research
    • 2.1.2. Primary Research
    • 2.1.3. Market Size Estimation

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Dynamics
  • 3.3. Product Segment Analysis
  • 3.4. Application Segment Analysis
  • 3.5. End User Analysis
  • 3.6. Regional Analysis
  • 3.7. Competitive Analysis

4. Market Overview

  • 4.1. Introduction
  • 4.2. Drivers
    • 4.2.1. Rising Cancer Incidence
    • 4.2.2. Growing Adoption of Immunotherapy over other Treatment Options
    • 4.2.3. Increasing Number of Technological Collaborations and Mergers
    • 4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
  • 4.3. Market Restraints
    • 4.3.1. High Cost of Treatment
  • 4.4. Market Opportunities
    • 4.4.1. Growing R&D Expenditure
    • 4.4.2. High Growth Prospects in Emerging Economies
  • 4.5. Market Challenges
    • 4.5.1. Limited Funds with Small and Mid-Sized Organizations to Initiate the Clinical Trials
    • 4.5.2. Complexities of Tumor

5. Industry Insights

  • 5.1. Key Industry Trends
    • 5.1.1. Personalized Immunotherapy
    • 5.1.2. Implementation of Next-Generation Sequencing Technologies
    • 5.1.3. Immunotherapy Combination
    • 5.1.4. Accelerated Approval
    • 5.1.5. China's Rapidly Expanding Cancer Immunotherapy Market
  • 5.2. Evolution of Cancer Immunotherapy
  • 5.3. Opdivo and Keytruda: Major Products in Cancer Immunotherapy Market

6. Cancer Immunotherapy Market, by Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Checkpoint Inhibitors
  • 6.4. Immunomodulators
  • 6.5. Vaccines
  • 6.6. Cell Therapies

7. Cancer Immunotherapy Market, by Application

  • 7.1. Introduction
  • 7.2. Lung Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Melanoma
  • 7.6. Prostate Cancer
  • 7.7. Multiple Myeloma
  • 7.8. Other Cancer Types

8. Cancer Immunotherapy Market, by End User

  • 8.1. Overview
  • 8.2. Hospitals
  • 8.3. Clinics and Others

9. Cancer Immunotherapy Market, by Region

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Rest of Europe
  • 9.4. Asia Pacific
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. India
    • 9.4.4. Rest of Asia Pacific
  • 9.5. Latin America
  • 9.6. Middle East & Africa

10. Competitive Landscape

  • 10.1. Introduction
  • 10.2. Market Share Analysis
  • 10.3. Competitor Benchmarking
  • 10.4. Competitive Situation and Trends
    • 10.4.1. Approvals
    • 10.4.2. Agreements and Collaborations
    • 10.4.3. Acquisitions
    • 10.4.4. Other Developments

11. Company Profiles

(Business Overview, Financial Overview, Product Portfolio, Recent Strategic Developments)

  • 11.1. Astrazeneca
  • 11.2. Amgen
  • 11.3. Bristol-Myers Squibb
  • 11.4. Eli Lilly
  • 11.5. Johnson & Johnson
  • 11.6. Merck & Co., Inc.
  • 11.7. Novartis International AG
  • 11.8. Pfizer Inc.
  • 11.9. F. Hoffmann-La Roche
  • 11.10. Celgene Corporation

12. Appendix

  • 12.1. Questionnaire
Back to Top